Sanofi Genzyme
500 Kendall Street
Cambridge
Massachusetts
02142
United States
Tel: 617-252-7500
Fax: 617-252-7600
Website: https://www.sanofigenzyme.com/
About Sanofi Genzyme
About Genzyme
Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.
Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
776 articles with Sanofi Genzyme
-
Canadian employers underestimate the proportion of their workforce with a chronic condition and its impact
6/13/2018
The 21st edition of The Sanofi Canada Healthcare Survey of Canadian employees with workplace health benefit plans (plan members) and of organizations who offer their employees health benefits (plan sponsors) indicates that while 58% of surveyed plan members report having at least one chronic disease or condition, plan sponsors underestimate the proportion of their workforce with a chronic condition (29%).
-
DTxDM - the Home of Validated Digital Healthcare, Announces Its Founding Partners at the Launch of the New Hub for Everyone Working in Digital Therapeutics and Digital Medicine
6/13/2018
DTxDM are delighted to announce that Sanofi, Dthera Sciences and Cognoa have joined as founding partners at the launch of the new DTxDM Hub.
-
Translate Bio, headquartered in Lexington, Massachusetts, and Paris-based Sanofi are teaming up to develop five vaccines.
-
BioSpace takes a look at some notable programs that have been shuttered so far this year.
-
New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
6/4/2018
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced that pivotal data from two trials evaluating cemiplimab in advanced cutaneous squamous cell carcinoma (CSCC) were published today in the New England Journal of Medicine (NEJM) and presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Roseanne Barr has courted controversy with comments concerning immigration, the Parkland school shooting, and various racist and anti-Semitic conspiracy theories. She later blamed these comments on her use of the sleep medication Ambien.
-
Adaptive Biotechnologies Announces a Collaboration with Sanofi to Use Adaptive’s clonoSEQ® Assay to Measure Minimal Residual Disease in Active and Future Isatuximab Multiple Myeloma Trials
5/29/2018
Adaptive Biotechnologies announced today that it entered into an agreement with Sanofi to utilize Adaptive’s NGS-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to isatuximab.
-
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
-
Hemophilia B patients have some good news to cheer. Data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of patients. However, uniQure wasn’t the only company touting positive news in the treatment of hemophilia.
-
Evotec and Celgene Enter into Strategic Oncology Partnership
5/22/2018
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation ("Celgene") have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.
-
The typical way for a biotech to launch is for a scientist, often academia-based, to have come up with a discovery that shows commercial promise—sometimes rather far down the line. Venture capital (VC) firms are on the alert for this type of thing (and vice versa).
-
Celgne's head of business development, George Golumbeski, has also left the company.
-
Regeneron Pharmaceuticals and its developmental partner Sanofi are eying the third quarter of this year to seek regulatory approval for Dupixent (dupilumab) as a potential monotherapy treatment for moderate-to-severe atopic dermatitis in adolescents.
-
Alnylam Pharmceuticals reported preclinical results that supports advancement of its RNA interference (RNAi) therapeutics for central nervous system disorders into the clinic.
-
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
-
Patent fights are nothing new in the pharmaceutical industry but a new report shows that during 2017 the number of legal battles of pharmaceutical patents increased by 30 percent.
-
Sam Isaly has finally stepped down from his position as a managing member OrbiMed more than four months after he was accused of sexual harassment. Sexual harassment allegations have been in the forefront of the news cycles for months as the #MeToo movement gained traction.
-
To ask the question, “What are the top biotech stocks?” is to get trapped in a maze of definitions: small cap versus large cap, upcoming catalysts, trending, or a byzantine series of technical evaluations. Rather than to attempt an overall view, here are a variety of biotech stocks that are worth...
-
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
-
Many of the trends that affect biopharma recruitment are trends that affect healthcare in general, as well as other industries.